



BRITISH COLUMBIA
CENTRE *for* EXCELLENCE
in HIV/AIDS

B.C. HIV/AIDS Drug Treatment Program

Monthly Report

November 2020





© 2021 BC Centre for Excellence in HIV/AIDS

DISCLAIMER: This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

BC Centre for Excellence in HIV/AIDS Drug Treatment Program

St. Paul's Hospital
608 - 1081 Burrard Street
Vancouver, BC
V6Z 1Y6

Tel: 604.806.8515
Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677
St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222
Website: www.cfenet.ubc.ca
Email: info@cfenet.ubc.ca

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)





EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to HIV-infected persons throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.





TABLE OF CONTENTS

1. List of Figures

- 1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2012 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART





Table of Contents, cont'd...

3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

4. Health Authority Tables

INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries

FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries

NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries

ABORIGINAL

- 4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

5. Appendix

- 5.1 Drug Names and Definitions






1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority

November 2020

N = 7368



Health Authority	Male	Female	All
FRASER	1446	437	1883
INTERIOR	422	99	521
NORTHERN	138	81	219
VANCOUVER COASTAL	3335	451	3786
VANCOUVER ISLAND	769	158	927
	6110	1226	7336
		Unknown/not stated:	32
		Total:	7368

Definitions:


On antiretroviral therapy defined as being on treatment in the current month

Unknown/not stated defined as being on treatment in the current month, and city of residence unknown






1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (November 2015 - November 2020)






1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (November 2015 - November 2020)






1.4 BC-CfE Enrollment: Net Number of New Antiretroviral Participants (November 2015 - November 2020)






1.5 BC-CfE Enrollment: New Antiretroviral Participants (November 2015 - November 2020)






1.6 Percent Distribution of Active Participants by CD4 Count (November 2015 - November 2020)






1.7 Percent Distribution of Inactive Participants by CD4 Count (November 2015 - November 2020)






1.8 Active and Inactive Participants (November 2015 - November 2020)






1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (November 2015 - November 2020)






1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (November 2015 - November 2020)






1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by INGREDIENT

(November 2015 - November 2020)






1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT (November 2015 - November 2020)






1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT

(November 2015 - November 2020)






1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT
(November 2015 - November 2020)






1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by INGREDIENT

(November 2015 - November 2020)






1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT (November 2015 - November 2020)






1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by INGREDIENT

(November 2015 - November 2020)






1.18 Baseline CD4 for Antiretroviral First Starts (November 2015 - November 2020)






1.19 DTP Participants with PVL Measurement within previous five years, and never on ART (November 2015 - November 2020)






1.20 Cumulative Resistance Testing Results by Resistance Category (November 2015 - November 2020)





1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category (November 2015 - November 2020)





**2.1 Duration of ARV treatment in the Province of BC, 1987-2020
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
1987	28	5	0	5	1	820	5	<40	4
1988	30	5	0	5	3	370	5	<40	3
1989	28	51	1	52	30	480	50	<40	3
1990	26	52	1	53	32	505	52	<40	3
1991	26	35	3	38	23	620	37	<40	3
1992	26	60	5	65	33	600	60	<40	3
1993	25	126	15	141	99	550	133	<40	3
1994	24	75	12	87	61	560	82	<40	3
1995	24	131	20	151	107	550	144	<40	3
1996	22	325	48	373	252	600	346	<40	3
1997	20	271	30	301	208	620	278	<40	3
1998	19	196	44	240	166	590	219	<40	3
1999	19	159	38	197	138	562	182	<40	3
2000	19	121	34	155	109	580	144	<40	3
2001	19	113	28	141	91	600	128	<40	3
2002	18	125	27	152	104	581	139	<40	3
2003	17	145	27	172	113	600	160	<40	3
2004	16	155	40	195	138	630	177	<40	3
2005	15	187	44	231	172	610	214	<40	3
2006	14	174	39	213	135	600	182	<40	3
2007	13	234	45	279	193	610	248	<40	3
2008	12	278	61	339	236	650	307	<40	3
2009	11	296	64	360	250	650	330	<40	3
2010	10	277	66	343	237	680	305	<40	3
2011	9	331	72	403	280	700	360	<40	3
2012	8	260	61	321	214	695	288	<40	3
2013	7	260	66	326	212	685	291	<40	3
2014	6	269	51	320	204	705	283	<40	3
2015	5	280	47	327	226	675	289	<40	3
2016	4	266	51	317	198	680	282	<40	3
2017	3	209	32	241	173	650	215	<40	3
2018	2	196	51	247	166	675	217	<40	3

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





**2.1 Duration of ARV treatment in the Province of BC, 1987-2020
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Current CD4 Median	Current PVL (n)	Current PVL Median	Current ARV Median
2019	1	239	51	290	219	640	261	<40	3
2020	1	195	56	251	202	625	235	<40	3
Total:		6101	1230	7331					

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2019	7393	787	2456	<40	2146	610
FEB-2019	7368	793	1854	<40	1583	620
MAR-2019	7407	790	2085	<40	1753	610
APR-2019	7358	796	2141	<40	1746	610
MAY-2019	7416	791	2127	<40	1766	620
JUN-2019	7358	803	1926	<40	1593	620
JUL-2019	7370	810	2111	<40	1695	620
AUG-2019	7366	807	2106	<40	1622	602
SEP-2019	7338	805	2011	<40	1568	600
OCT-2019	7389	781	2140	<40	1746	620
NOV-2019	7342	779	2026	<40	1581	630
DEC-2019	7342	777	1700	<40	1297	610
JAN-2020	7358	774	2226	<40	1724	610
FEB-2020	7330	776	1882	<40	1414	620
MAR-2020	7387	768	1628	<40	1206	620
APR-2020	7408	770	767	<40	575	590
MAY-2020	7398	776	1186	<40	886	600
JUN-2020	7374	783	1558	<40	1140	620
JUL-2020	7344	794	1917	<40	1430	610
AUG-2020	7268	791	1848	<40	1316	630
SEP-2020	7252	784	1735	<40	1218	620
OCT-2020	7285	775	1781	<40	1245	640
NOV-2020	7368	763	1859	<40	1212	610

Definitions:

Active patient defined as being on ARV treatment in the specified month

Therapy days defined as number of consecutive days on ARV treatment (most recent uninterrupted period)

PVL and CD4 tests defined as tests done in the specified month





2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2019	627	193	73	73	65	350
FEB-2019	658	156	75	108	66	590
MAR-2019	628	168	73	729	60	400
APR-2019	671	157	81	<50	71	480
MAY-2019	616	201	77	91	69	440
JUN-2019	679	160	78	<40	71	510
JUL-2019	667	162	70	<40	58	525
AUG-2019	686	167	80	50	67	510
SEP-2019	716	152	96	<40	81	580
OCT-2019	658	193	81	102	69	470
NOV-2019	678	180	68	<40	58	560
DEC-2019	665	180	56	<40	48	480
JAN-2020	641	191	71	255	47	460
FEB-2020	682	176	72	<40	59	480
MAR-2020	640	193	54	<40	37	470
APR-2020	619	207	28	116	22	555
MAY-2020	638	196	43	<40	31	490
JUN-2020	670	184	58	<40	48	480
JUL-2020	737	163	73	<40	57	620
AUG-2020	828	144	77	<40	65	480
SEP-2020	876	141	97	<40	69	610
OCT-2020	868	185	88	<40	70	560
NOV-2020	797	199	77	<40	58	510

Definitions:

Inactive patient defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs), and had contact with program in past 5 years

Days off therapy defined as number of days elapsed since last ARV treatment

PVL and CD4 tests defined as tests done in the specified month





2.4 BC-CfE Enrollment

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2019	7364	627	14	20	191	159	35	13564
FEB-2019	7346	658	7	16	160	181	-18	13593
MAR-2019	7367	628	15	13	187	149	21	13613
APR-2019	7324	671	10	15	152	182	-43	13641
MAY-2019	7389	616	11	21	197	136	65	13683
JUN-2019	7329	679	14	13	136	191	-60	13704
JUL-2019	7343	667	13	13	181	164	14	13727
AUG-2019	7338	686	12	18	170	174	-5	13763
SEP-2019	7310	716	14	15	181	204	-28	13790
OCT-2019	7323	658	3	13	223	150	13	13819
NOV-2019	7316	678	9	17	165	170	-7	13852
DEC-2019	7311	665	8	12	164	157	-5	13879
JAN-2020	7330	641	10	13	183	155	19	13903
FEB-2020	7296	682	12	19	141	173	-34	13939
MAR-2020	7358	640	14	23	210	153	62	13975
APR-2020	7382	619	12	8	158	127	24	14000
MAY-2020	7375	638	10	15	130	135	-7	14025
JUN-2020	7346	670	8	9	125	149	-29	14042
JUL-2020	7310	737	15	12	160	189	-36	14074
AUG-2020	7226	828	18	11	169	241	-84	14094
SEP-2020	7204	876	19	9	231	238	-22	14115
OCT-2020	7242	868	20	13	223	173	38	14136
NOV-2020	7331	797	9	11	246	158	89	14161

Definitions:

Currently on ARV Therapy defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

Currently off ARV Therapy defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

Deceased defined as deceased in the specified month, and being on ARV treatment in the previous month

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Experienced Starts defined as starting ARV treatment in the specified month, but previously being treated with ARVs

New Inactive defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month, and had contact with the program in the past 5 years

Net Change is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)





2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2019	55	6800	485	53	7393	0.74%	91.98%	6.56%	0.72%	100.00%
FEB-2019	54	6775	490	49	7368	0.73%	91.95%	6.65%	0.67%	100.00%
MAR-2019	60	6808	489	50	7407	0.81%	91.91%	6.60%	0.68%	100.00%
APR-2019	57	6764	489	48	7358	0.77%	91.93%	6.65%	0.65%	100.00%
MAY-2019	56	6824	491	45	7416	0.76%	92.02%	6.62%	0.61%	100.00%
JUN-2019	58	6771	481	48	7358	0.79%	92.02%	6.54%	0.65%	100.00%
JUL-2019	61	6772	489	48	7370	0.83%	91.89%	6.64%	0.65%	100.00%
AUG-2019	60	6775	481	50	7366	0.81%	91.98%	6.53%	0.68%	100.00%
SEP-2019	57	6744	486	51	7338	0.78%	91.91%	6.62%	0.70%	100.00%
OCT-2019	61	6788	488	52	7389	0.83%	91.87%	6.60%	0.70%	100.00%
NOV-2019	60	6746	486	50	7342	0.82%	91.88%	6.62%	0.68%	100.00%
DEC-2019	61	6755	478	48	7342	0.83%	92.00%	6.51%	0.65%	100.00%
JAN-2020	60	6758	484	56	7358	0.82%	91.85%	6.58%	0.76%	100.00%
FEB-2020	59	6736	476	59	7330	0.80%	91.90%	6.49%	0.80%	100.00%
MAR-2020	60	6790	486	51	7387	0.81%	91.92%	6.58%	0.69%	100.00%
APR-2020	61	6814	483	50	7408	0.82%	91.98%	6.52%	0.67%	100.00%
MAY-2020	60	6807	481	50	7398	0.81%	92.01%	6.50%	0.68%	100.00%
JUN-2020	59	6779	485	51	7374	0.80%	91.93%	6.58%	0.69%	100.00%
JUL-2020	62	6762	472	48	7344	0.84%	92.08%	6.43%	0.65%	100.00%
AUG-2020	71	6688	458	51	7268	0.98%	92.02%	6.30%	0.70%	100.00%
SEP-2020	86	6656	458	52	7252	1.19%	91.78%	6.32%	0.72%	100.00%
OCT-2020	107	6664	463	51	7285	1.47%	91.48%	6.36%	0.70%	100.00%
NOV-2020	162	6700	457	49	7368	2.20%	90.93%	6.20%	0.67%	100.00%

Definitions:

Number of Drugs is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)





2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT

	lamivudine		abacavir		zidovudine		stavudine		didanosine		tenofovir <TAF>		tenofovir <TDF>	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2019	8 23%	3467 48%	7 20%	3254 45%	1 3%	45 1%	0 0%	4 0%	0 0%	1 0%	1 3%	519 7%	26 74%	3358 47%
FEB-2019	13 45%	3457 48%	12 41%	3256 45%	0 0%	44 1%	0 0%	1 0%	0 0%	1 0%	3 10%	541 8%	13 45%	3306 46%
MAR-2019	6 30%	3470 48%	6 30%	3274 45%	0 0%	43 1%	0 0%	2 0%	0 0%	0 0%	2 10%	559 8%	12 60%	3305 46%
APR-2019	12 43%	3469 48%	12 43%	3278 46%	0 0%	43 1%	0 0%	2 0%	0 0%	0 0%	2 7%	586 8%	14 50%	3245 45%
MAY-2019	14 34%	3498 48%	14 34%	3308 46%	0 0%	43 1%	0 0%	2 0%	0 0%	1 0%	4 10%	593 8%	23 56%	3258 45%
JUN-2019	3 14%	3479 49%	3 14%	3291 46%	0 0%	43 1%	0 0%	2 0%	0 0%	1 0%	2 10%	608 8%	16 76%	3198 45%
JUL-2019	8 36%	3504 49%	8 36%	3325 46%	0 0%	38 1%	0 0%	1 0%	0 0%	1 0%	1 5%	625 9%	13 59%	3177 44%
AUG-2019	14 39%	3515 49%	12 33%	3340 47%	2 6%	41 1%	0 0%	1 0%	0 0%	1 0%	2 6%	630 9%	20 56%	3144 44%
SEP-2019	5 19%	3494 49%	5 19%	3318 46%	0 0%	39 1%	0 0%	1 0%	0 0%	1 0%	5 19%	653 9%	17 63%	3121 44%
OCT-2019	4 14%	3513 49%	2 7%	3331 46%	0 0%	38 1%	0 0%	1 0%	0 0%	1 0%	1 4%	668 9%	23 82%	3142 44%
NOV-2019	8 24%	3458 48%	7 21%	3281 46%	1 3%	37 1%	0 0%	1 0%	0 0%	1 0%	6 18%	728 10%	19 58%	3113 44%
DEC-2019	1 4%	3436 48%	1 4%	3258 46%	0 0%	37 1%	0 0%	1 0%	0 0%	1 0%	13 48%	855 12%	13 48%	3051 43%
JAN-2020	2 8%	3402 47%	2 8%	3226 45%	0 0%	34 0%	0 0%	1 0%	0 0%	0 0%	9 38%	1024 14%	13 54%	2963 41%
FEB-2020	3 8%	3352 47%	3 8%	3180 45%	0 0%	33 0%	0 0%	1 0%	0 0%	0 0%	16 44%	1169 16%	17 47%	2825 40%
MAR-2020	5 14%	3325 46%	5 14%	3160 44%	1 3%	34 0%	0 0%	1 0%	0 0%	0 0%	20 56%	1326 18%	11 31%	2719 38%
APR-2020	6 24%	3298 46%	5 20%	3137 43%	1 4%	35 0%	0 0%	0 0%	0 0%	0 0%	8 32%	1402 19%	11 44%	2637 37%
MAY-2020	1 4%	3273 45%	0 0%	3112 43%	0 0%	36 0%	0 0%	0 0%	0 0%	0 0%	13 54%	1481 21%	11 46%	2595 36%
JUN-2020	5 29%	3244 45%	5 29%	3082 43%	0 0%	33 0%	0 0%	0 0%	0 0%	0 0%	4 24%	1587 22%	8 47%	2519 35%
JUL-2020	6 19%	3205 45%	4 13%	3045 43%	2 6%	32 0%	0 0%	0 0%	0 0%	0 0%	14 44%	1697 24%	12 38%	2422 34%
AUG-2020	3 15%	3154 45%	2 10%	2994 42%	0 0%	31 0%	0 0%	0 0%	0 0%	0 0%	11 55%	1763 25%	6 30%	2317 33%
SEP-2020	3 14%	3128 44%	2 10%	2967 42%	0 0%	32 0%	0 0%	0 0%	0 0%	0 0%	13 62%	1875 27%	5 24%	2228 32%
OCT-2020	2 10%	3129 44%	2 10%	2952 42%	0 0%	30 0%	0 0%	0 0%	0 0%	0 0%	12 57%	1976 28%	7 33%	2140 30%
NOV-2020	7 28%	3171 44%	3 12%	2940 41%	1 4%	32 0%	0 0%	0 0%	0 0%	0 0%	10 40%	2073 29%	8 32%	2087 29%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (continued)

	emtricitabine			
	Initial		All	
JAN-2019	27	77%	3697	51%
FEB-2019	16	55%	3674	51%
MAR-2019	14	70%	3702	51%
APR-2019	16	57%	3662	51%
MAY-2019	27	66%	3689	51%
JUN-2019	18	86%	3643	51%
JUL-2019	14	64%	3650	51%
AUG-2019	22	61%	3626	51%
SEP-2019	22	81%	3622	51%
OCT-2019	24	86%	3663	51%
NOV-2019	25	76%	3671	51%
DEC-2019	26	96%	3713	52%
JAN-2020	22	92%	3763	52%
FEB-2020	33	92%	3781	53%
MAR-2020	30	83%	3855	54%
APR-2020	19	76%	3888	54%
MAY-2020	23	96%	3914	54%
JUN-2020	12	71%	3925	55%
JUL-2020	26	81%	3946	55%
AUG-2020	17	85%	3921	55%
SEP-2020	18	86%	3938	56%
OCT-2020	19	90%	3971	56%
NOV-2020	18	72%	4010	56%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.7 Number of Participants on Protease Inhibitor by INGREDIENT

	fosamprenavir		atazanavir		darunavir		lopinavir		nelfinavir		ritonavir		saquinavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2019	0 0%	6 0%	1 8%	1097 40%	11 92%	1475 54%	0 0%	140 5%	0 0%	0 0%	0 0%	1 0%	0 0%	9 0%
FEB-2019	0 0%	5 0%	2 18%	1069 40%	9 82%	1472 55%	0 0%	138 5%	0 0%	0 0%	0 0%	1 0%	0 0%	9 0%
MAR-2019	0 0%	5 0%	2 40%	1053 39%	3 60%	1486 55%	0 0%	132 5%	0 0%	1 0%	0 0%	1 0%	0 0%	7 0%
APR-2019	0 0%	5 0%	1 10%	1027 39%	7 70%	1477 56%	2 20%	132 5%	0 0%	2 0%	0 0%	1 0%	0 0%	7 0%
MAY-2019	0 0%	5 0%	1 8%	1033 39%	11 92%	1478 56%	0 0%	130 5%	0 0%	2 0%	0 0%	1 0%	0 0%	6 0%
JUN-2019	0 0%	5 0%	0 0%	1001 39%	9 100%	1464 57%	0 0%	119 5%	0 0%	1 0%	0 0%	1 0%	0 0%	6 0%
JUL-2019	0 0%	5 0%	0 0%	981 38%	6 100%	1482 58%	0 0%	111 4%	0 0%	1 0%	0 0%	1 0%	0 0%	6 0%
AUG-2019	0 0%	5 0%	0 0%	968 38%	11 92%	1459 57%	1 8%	112 4%	0 0%	1 0%	0 0%	1 0%	0 0%	5 0%
SEP-2019	0 0%	4 0%	1 8%	954 37%	12 92%	1481 58%	0 0%	110 4%	0 0%	1 0%	0 0%	1 0%	0 0%	6 0%
OCT-2019	0 0%	4 0%	1 7%	957 37%	13 93%	1489 58%	0 0%	109 4%	0 0%	1 0%	0 0%	1 0%	0 0%	6 0%
NOV-2019	0 0%	4 0%	0 0%	940 37%	3 100%	1469 58%	0 0%	101 4%	0 0%	1 0%	0 0%	1 0%	0 0%	6 0%
DEC-2019	0 0%	4 0%	0 0%	923 37%	7 100%	1466 59%	0 0%	100 4%	0 0%	1 0%	0 0%	1 0%	0 0%	6 0%
JAN-2020	0 0%	2 0%	0 0%	910 37%	6 86%	1466 59%	1 14%	96 4%	0 0%	0 0%	0 0%	1 0%	0 0%	6 0%
FEB-2020	0 0%	2 0%	1 11%	873 36%	8 89%	1454 60%	0 0%	96 4%	0 0%	0 0%	0 0%	1 0%	0 0%	6 0%
MAR-2020	0 0%	2 0%	1 10%	860 36%	9 90%	1434 60%	0 0%	93 4%	0 0%	0 0%	0 0%	1 0%	0 0%	6 0%
APR-2020	0 0%	2 0%	0 0%	838 36%	4 80%	1412 60%	1 20%	93 4%	0 0%	0 0%	0 0%	1 0%	0 0%	6 0%
MAY-2020	0 0%	2 0%	1 10%	834 36%	9 90%	1411 60%	0 0%	89 4%	0 0%	0 0%	0 0%	0 0%	0 0%	6 0%
JUN-2020	0 0%	2 0%	2 33%	813 35%	4 67%	1388 61%	0 0%	86 4%	0 0%	0 0%	0 0%	1 0%	0 0%	6 0%
JUL-2020	0 0%	1 0%	0 0%	782 35%	8 100%	1362 61%	0 0%	81 4%	0 0%	0 0%	0 0%	1 0%	0 0%	6 0%
AUG-2020	0 0%	1 0%	1 20%	752 35%	4 80%	1331 62%	0 0%	79 4%	0 0%	0 0%	0 0%	1 0%	0 0%	6 0%
SEP-2020	0 0%	0 0%	1 33%	737 35%	2 67%	1305 61%	0 0%	79 4%	0 0%	0 0%	0 0%	1 0%	0 0%	6 0%
OCT-2020	0 0%	0 0%	0 0%	713 34%	6 100%	1286 62%	0 0%	77 4%	0 0%	0 0%	0 0%	1 0%	0 0%	6 0%
NOV-2020	0 0%	1 0%	0 0%	698 34%	3 100%	1275 62%	0 0%	77 4%	0 0%	0 0%	0 0%	1 0%	0 0%	6 0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.7 Number of Participants on Protease Inhibitor by INGREDIENT (continued)

	tipranavir			
	Initial		All	
JAN-2019	0	0%	1	0%
FEB-2019	0	0%	1	0%
MAR-2019	0	0%	1	0%
APR-2019	0	0%	1	0%
MAY-2019	0	0%	1	0%
JUN-2019	0	0%	1	0%
JUL-2019	0	0%	1	0%
AUG-2019	0	0%	1	0%
SEP-2019	0	0%	1	0%
OCT-2019	0	0%	1	0%
NOV-2019	0	0%	1	0%
DEC-2019	0	0%	1	0%
JAN-2020	0	0%	1	0%
FEB-2020	0	0%	1	0%
MAR-2020	0	0%	1	0%
APR-2020	0	0%	1	0%
MAY-2020	0	0%	0	0%
JUN-2020	0	0%	1	0%
JUL-2020	0	0%	1	0%
AUG-2020	0	0%	1	0%
SEP-2020	0	0%	1	0%
OCT-2020	0	0%	1	0%
NOV-2020	0	0%	1	0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.8 Number of Participants on Non-Nucleosides by INGREDIENT

	doravirine		efavirenz		etravirine		nevirapine		rilpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2019	0 0%	0 0%	4 80%	669 35%	0 0%	221 12%	1 20%	695 37%	0 0%	318 17%
FEB-2019	0 0%	0 0%	2 67%	667 35%	1 33%	226 12%	0 0%	683 36%	0 0%	313 17%
MAR-2019	0 0%	0 0%	3 75%	660 35%	0 0%	223 12%	1 25%	680 36%	0 0%	322 17%
APR-2019	0 0%	0 0%	4 100%	645 35%	0 0%	222 12%	0 0%	677 36%	0 0%	320 17%
MAY-2019	0 0%	0 0%	5 100%	647 35%	0 0%	217 12%	0 0%	672 36%	0 0%	322 17%
JUN-2019	0 0%	0 0%	3 75%	633 35%	0 0%	211 12%	0 0%	664 36%	1 25%	320 18%
JUL-2019	0 0%	1 0%	2 100%	633 35%	0 0%	209 11%	0 0%	657 36%	0 0%	322 18%
AUG-2019	0 0%	1 0%	2 100%	624 35%	0 0%	205 11%	0 0%	647 36%	0 0%	324 18%
SEP-2019	0 0%	1 0%	4 80%	607 34%	0 0%	207 12%	0 0%	622 35%	1 20%	324 18%
OCT-2019	0 0%	1 0%	6 60%	608 35%	1 10%	209 12%	2 20%	596 34%	1 10%	330 19%
NOV-2019	0 0%	1 0%	5 71%	612 37%	0 0%	208 12%	1 14%	525 31%	1 14%	326 20%
DEC-2019	0 0%	1 0%	3 100%	607 37%	0 0%	203 12%	0 0%	513 31%	0 0%	324 20%
JAN-2020	0 0%	1 0%	3 100%	590 36%	0 0%	202 12%	0 0%	501 31%	0 0%	325 20%
FEB-2020	0 0%	1 0%	4 100%	558 36%	0 0%	198 13%	0 0%	483 31%	0 0%	320 21%
MAR-2020	0 0%	1 0%	4 100%	547 36%	0 0%	195 13%	0 0%	464 31%	0 0%	315 21%
APR-2020	0 0%	1 0%	6 86%	542 36%	0 0%	190 13%	0 0%	456 30%	1 14%	313 21%
MAY-2020	0 0%	1 0%	1 50%	536 36%	0 0%	193 13%	0 0%	452 30%	1 50%	305 21%
JUN-2020	0 0%	1 0%	2 100%	524 36%	0 0%	189 13%	0 0%	448 30%	0 0%	307 21%
JUL-2020	0 0%	3 0%	2 50%	507 35%	0 0%	184 13%	2 50%	439 31%	0 0%	305 21%
AUG-2020	1 100%	4 0%	0 0%	501 36%	0 0%	179 13%	0 0%	423 30%	0 0%	294 21%
SEP-2020	0 0%	5 0%	1 33%	476 35%	0 0%	174 13%	0 0%	410 30%	2 67%	294 22%
OCT-2020	0 0%	9 1%	1 100%	463 35%	0 0%	173 13%	0 0%	402 30%	0 0%	279 21%
NOV-2020	0 0%	10 1%	2 67%	454 35%	0 0%	172 13%	1 33%	393 30%	0 0%	279 21%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Doravirine not currently available on BC-CfE Formulary





2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT

	bictegravir		dolutegravir		elvitegravir		maraviroc		raltegravir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2019	0 0%	16 0%	15 75%	2429 63%	4 20%	729 19%	0 0%	39 1%	1 5%	651 17%
FEB-2019	0 0%	27 1%	16 73%	2431 63%	5 23%	726 19%	0 0%	40 1%	1 5%	651 17%
MAR-2019	0 0%	27 1%	8 62%	2479 64%	5 38%	745 19%	0 0%	38 1%	0 0%	647 17%
APR-2019	0 0%	27 1%	8 57%	2493 64%	3 21%	736 19%	0 0%	36 1%	3 21%	636 16%
MAY-2019	0 0%	27 1%	19 68%	2554 64%	6 21%	746 19%	0 0%	37 1%	3 11%	634 16%
JUN-2019	0 0%	27 1%	10 77%	2556 65%	3 23%	743 19%	0 0%	37 1%	0 0%	624 16%
JUL-2019	0 0%	27 1%	13 81%	2603 65%	3 19%	755 19%	0 0%	38 1%	0 0%	628 16%
AUG-2019	0 0%	27 1%	24 86%	2647 65%	1 4%	755 19%	0 0%	36 1%	3 11%	625 15%
SEP-2019	0 0%	28 1%	7 47%	2648 65%	6 40%	757 19%	0 0%	37 1%	2 13%	627 15%
OCT-2019	0 0%	28 1%	13 87%	2717 66%	1 7%	758 18%	0 0%	34 1%	1 7%	628 15%
NOV-2019	3 13%	88 2%	16 70%	2741 65%	4 17%	770 18%	0 0%	33 1%	0 0%	621 15%
DEC-2019	12 63%	230 5%	6 32%	2716 64%	1 5%	744 18%	0 0%	33 1%	0 0%	606 14%
JAN-2020	9 50%	421 10%	7 39%	2687 62%	0 0%	707 16%	0 0%	32 1%	2 11%	594 14%
FEB-2020	14 52%	602 14%	11 41%	2644 60%	2 7%	654 15%	0 0%	29 1%	0 0%	576 13%
MAR-2020	19 68%	755 17%	7 25%	2624 58%	1 4%	623 14%	1 4%	30 1%	0 0%	562 12%
APR-2020	7 50%	827 18%	6 43%	2589 57%	1 7%	607 13%	0 0%	29 1%	0 0%	544 12%
MAY-2020	10 56%	911 20%	6 33%	2555 56%	2 11%	597 13%	0 0%	27 1%	0 0%	541 12%
JUN-2020	4 31%	1024 22%	9 69%	2538 55%	0 0%	582 13%	1 8%	28 1%	0 0%	538 12%
JUL-2020	9 38%	1142 24%	10 42%	2512 54%	5 21%	549 12%	0 0%	29 1%	0 0%	527 11%
AUG-2020	10 59%	1221 26%	6 35%	2462 52%	1 6%	517 11%	0 0%	29 1%	0 0%	521 11%
SEP-2020	13 87%	1341 28%	2 13%	2443 51%	0 0%	498 10%	0 0%	29 1%	0 0%	504 11%
OCT-2020	10 59%	1447 30%	5 29%	2432 50%	0 0%	493 10%	0 0%	30 1%	2 12%	495 10%
NOV-2020	8 38%	1549 31%	8 38%	2480 50%	2 10%	482 10%	0 0%	27 1%	3 14%	490 10%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class

MON-YYYY	Boosted PI + 2 NRTIs		NNRTI + 2 NRTIs		Integrase + 2 NRTIs		Un-boosted PI + 2 NRTIs		MDRT		Other	
	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2019	1830	24.75	1481	20.03	3061	41.40	100	1.35	53	0.72	868	11.74
FEB-2019	1802	24.46	1478	20.06	3072	41.69	99	1.34	49	0.67	868	11.78
MAR-2019	1794	24.22	1471	19.86	3124	42.18	98	1.32	50	0.68	870	11.75
APR-2019	1760	23.92	1458	19.82	3135	42.61	100	1.36	48	0.65	857	11.65
MAY-2019	1773	23.91	1448	19.53	3196	43.10	97	1.31	45	0.61	857	11.56
JUN-2019	1738	23.62	1438	19.54	3195	43.42	95	1.29	48	0.65	844	11.47
JUL-2019	1712	23.23	1427	19.36	3236	43.91	92	1.25	48	0.65	855	11.60
AUG-2019	1686	22.89	1402	19.03	3295	44.73	94	1.28	50	0.68	839	11.39
SEP-2019	1697	23.13	1361	18.55	3298	44.94	93	1.27	51	0.70	838	11.42
OCT-2019	1702	23.03	1339	18.12	3357	45.43	93	1.26	52	0.70	846	11.45
NOV-2019	1666	22.69	1272	17.32	3424	46.64	91	1.24	50	0.68	839	11.43
DEC-2019	1643	22.38	1248	17.00	3483	47.44	92	1.25	48	0.65	828	11.28
JAN-2020	1617	21.98	1210	16.44	3562	48.41	87	1.18	56	0.76	826	11.23
FEB-2020	1573	21.46	1154	15.74	3644	49.71	85	1.16	59	0.80	815	11.12
MAR-2020	1540	20.85	1134	15.35	3755	50.83	85	1.15	51	0.69	822	11.13
APR-2020	1522	20.55	1129	15.24	3807	51.39	85	1.15	50	0.67	815	11.00
MAY-2020	1512	20.44	1111	15.02	3831	51.78	83	1.12	50	0.68	811	10.96
JUN-2020	1460	19.80	1085	14.71	3883	52.66	83	1.13	51	0.69	812	11.01
JUL-2020	1424	19.39	1059	14.42	3939	53.64	79	1.08	48	0.65	795	10.83
AUG-2020	1380	18.99	1028	14.14	3948	54.32	78	1.07	51	0.70	783	10.77
SEP-2020	1343	18.52	982	13.54	4005	55.23	76	1.05	52	0.72	794	10.95
OCT-2020	1312	18.01	966	13.26	4069	55.85	76	1.04	51	0.70	811	11.13
NOV-2020	1294	17.56	949	12.88	4143	56.23	75	1.02	49	0.67	858	11.64

Definitions:

n is number of participants on the specified regimen class in the specified month
 % is ratio of n and total number of participants on ART in the specified month





2.11 Baseline CD4 for Antiretroviral First Starts

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2019	20	3	3	2	4	6	390
FEB-2019	16	1	0	6	4	4	400
MAR-2019	13	1	2	1	5	4	450
APR-2019	15	3	3	1	2	4	340
MAY-2019	21	1	0	6	8	4	440
JUN-2019	13	2	1	1	2	5	430
JUL-2019	13	1	1	1	3	7	530
AUG-2019	18	0	1	6	4	6	390
SEP-2019	15	0	0	2	4	7	530
OCT-2019	13	1	1	4	4	3	380
NOV-2019	17	4	1	1	1	10	520
DEC-2019	12	0	2	4	2	4	350
JAN-2020	13	0	2	1	4	4	490
FEB-2020	19	5	1	5	3	5	320
MAR-2020	23	4	0	3	1	10	550
APR-2020	8	0	0	3	0	5	686
MAY-2020	15	1	0	3	4	7	400
JUN-2020	9	1	0	3	4	1	380
JUL-2020	12	3	0	0	2	4	500
AUG-2020	11	3	1	3	2	1	225
SEP-2020	9	3	2	1	0	0	71
OCT-2020	13	2	1	1	3	3	381
NOV-2020	11	0	1	0	2	6	710

Definitions:

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Baseline CD4 is defined as most recent CD4 test before ARV start





2.12 DTP Participants with PVL Measurement within previous five years, and never on ART

MON-YYYY	# of Participants with PVL test	# of Participants with PVL test, and never on ART
JAN-2019	12250	3828
FEB-2019	12257	3826
MAR-2019	12287	3856
APR-2019	12313	3879
MAY-2019	12329	3880
JUN-2019	12329	3885
JUL-2019	12346	3900
AUG-2019	12378	3917
SEP-2019	12397	3935
OCT-2019	12431	3959
NOV-2019	12452	3967
DEC-2019	12476	3982
JAN-2020	12531	4028
FEB-2020	12562	4045
MAR-2020	12562	4035
APR-2020	12540	4011
MAY-2020	12529	3998
JUN-2020	12507	3976
JUL-2020	12484	3943
AUG-2020	12453	3920
SEP-2020	12415	3891
OCT-2020	12392	3878
NOV-2020	12413	3884

Definitions:

Patients with PVL test are defined as having at least one PVL test within previous five years, and not reported deceased/moved
Never on ART are subset of patients with PVL test, and not being treated with ARVs on or before specified month







3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
November 2020

N = 7368

BY HEALTH SERVICES DELIVERY AREA



BY HEALTH AUTHORITY







3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participants

November 2020

FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



SURREY BY POSTAL CODE







3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participants

November 2020

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VANCOUVER BY POSTAL CODE







3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participants

November 2020

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VICTORIA BY POSTAL CODE







3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participants

November 2020

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE





4.1 Distribution of Participants in BC-CfE Registries by Age and Gender INTERIOR Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST KOOTENAY	20-34	5	5	*
	35-49	9	10	*
	50+	27	39	*
	Total HSDA:	41	54	25
KOOTENAY BOUNDARY	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	74	99	59	
OKANAGAN	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	384	518	294	
THOMPSON/CARIBOO/ SHUSWAP	20-34	18	18	8
	35-49	68	74	51
	50+	108	179	84
	Total HSDA:	194	271	143
Total HA:		693	942	521

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HA:		693	942	521

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	554	753	422
Female	139	189	99

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	521	55	620	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration INTERIOR Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
EAST KOOTENAY	10 years or more	20	11
	5 years or more	11	7
	<5 years	10	7
	Total HSDA:	41	25
KOOTENAY BOUNDARY	10 years or more	48	37
	5 years or more	15	11
	<5 years	11	11
	Total HSDA:	74	59
OKANAGAN	10 years or more	234	168
	5 years or more	85	70
	<5 years	65	56
	Total HSDA:	384	294
THOMPSON/CARIBOO/ SHUSWAP	10 years or more	106	81
	5 years or more	46	37
	<5 years	42	25
	Total HSDA:	194	143
Total HA:		693	521

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	408	297
5 years or more	157	125
<5 years	128	99
Total HA:	693	521

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries INTERIOR Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
EAST KOOTENAY	46	64	15	27
KOOTENAY BOUNDARY	75	124	26	44
OKANAGAN	230	956	62	294
THOMPSON/CARIBOO/SHUSWAP	140	524	38	130
Total:	491	1668	141	495

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
EAST KOOTENAY	*
KOOTENAY BOUNDARY	*
OKANAGAN	*
THOMPSON/CARIBOO/SHUSWAP	*
Total:	90

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.4 Distribution of Participants in BC-CfE Registries by Age and Gender FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
FRASER EAST	0-19	6	6	6
	20-34	32	34	23
	35-49	99	109	69
	50+	241	322	188
	Total HSDA:	378	471	286
FRASER NORTH	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	1050	1422	785
FRASER SOUTH	0-19	6	6	*
	20-34	112	114	*
	35-49	324	365	*
	50+	567	843	*
	Total HSDA:	1009	1328	812
Total HA:		2437	3221	1883

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	15	15	10
	20-34	264	268	178
	35-49	754	831	575
	50+	1404	2107	1120
Total HA:		2437	3221	1883

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	1841	2462	1446
Female	596	759	437

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	1883	52	640	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
FRASER Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
FRASER EAST	10 years or more	227	176
	5 years or more	82	60
	<5 years	69	50
	Total HSDA:	378	286
FRASER NORTH	10 years or more	616	439
	5 years or more	244	195
	<5 years	190	151
	Total HSDA:	1050	785
FRASER SOUTH	10 years or more	594	473
	5 years or more	221	169
	<5 years	194	170
	Total HSDA:	1009	812
Total HA:		2437	1883

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	1437	1088
	5 years or more	547	424
	<5 years	453	371
Total HA:		2437	1883

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries FRASER Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
FRASER EAST	143	523	30	59
FRASER NORTH	254	1587	48	221
FRASER SOUTH	221	1607	48	491
Total:	618	3717	126	771

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
FRASER EAST	192
FRASER NORTH	650
FRASER SOUTH	440
Total:	1282

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.7 Distribution of Participants in BC-CfE Registries by Age and Gender VANCOUVER COASTAL Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		347	499
RICHMOND	20-34	36	37	26
	35-49	46	47	36
	50+	111	159	85
	Total HSDA:	193	243	147
VANCOUVER	0-19	14	14	9
	20-34	441	455	286
	35-49	1342	1504	952
	50+	2893	4988	2112
	Total HSDA:	4690	6961	3359
Total HA:		5230	7703	3786

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	15	15	10
	20-34	499	514	329
	35-49	1469	1642	1046
	50+	3247	5532	2401
Total HA:		5230	7703	3786

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Unknown	2	2	0
Male	4614	6756	3335
Female	614	945	451

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	3786	54	650	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER COASTAL Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	10 years or more	200	157
	5 years or more	87	71
	<5 years	60	52
	Total HSDA:	347	280
RICHMOND	10 years or more	110	77
	5 years or more	37	29
	<5 years	46	41
	Total HSDA:	193	147
VANCOUVER	10 years or more	2939	2031
	5 years or more	1057	776
	<5 years	694	552
	Total HSDA:	4690	3359
Total HA:		5230	3786

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	3249	2265
	5 years or more	1181	876
	<5 years	800	645
Total HA:		5230	3786

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries
VANCOUVER COASTAL Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH SHORE/COAST GARIBALDI	177	404	55	84
RICHMOND	43	292	10	92
VANCOUVER	632	11022	209	5267
Total:	852	11718	274	5443

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH SHORE/COAST GARIBALDI	5
RICHMOND	6
VANCOUVER	74
Total:	85

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER ISLAND Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		331	472
NORTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		123	166
SOUTH VANCOUVER ISLAND	20-34	75	79	50
	35-49	188	218	139
	50+	485	772	370
	Total HSDA:	748	1069	559
Total HA:		1202	1707	927

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HA:		1202	1707	927

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	993	1407	769
Female	209	300	158

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	927	55	570	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER ISLAND Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	10 years or more	197	162
	5 years or more	69	55
	<5 years	65	53
	Total HSDA:	331	270
NORTH VANCOUVER ISLAND	10 years or more	73	58
	5 years or more	35	26
	<5 years	15	14
	Total HSDA:	123	98
SOUTH VANCOUVER ISLAND	10 years or more	442	313
	5 years or more	155	126
	<5 years	151	120
	Total HSDA:	748	559
Total HA:		1202	927

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	712	533
	5 years or more	259	207
	<5 years	231	187
Total HA:		1202	927

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries VANCOUVER ISLAND Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
CENTRAL VANCOUVER ISLAND	197	885	77	198
NORTH VANCOUVER ISLAND	150	269	46	73
SOUTH VANCOUVER ISLAND	215	1830	43	550
Total:	562	2984	166	821

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
CENTRAL VANCOUVER ISLAND	46
NORTH VANCOUVER ISLAND	41
SOUTH VANCOUVER ISLAND	111
Total:	198

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.13 Distribution of Participants in BC-CfE Registries by Age and Gender NORTHERN Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH EAST	20-34	5	5	*
	35-49	17	20	*
	50+	21	27	*
	Total HSDA:	43	52	24
NORTH WEST	20-34	8	9	*
	35-49	21	36	*
	50+	37	64	*
	Total HSDA:	66	109	53
NORTHERN INTERIOR	0-19	6	6	*
	20-34	24	25	*
	35-49	66	84	*
	50+	100	167	*
	Total HSDA:	196	282	142
Total HA:		305	443	219

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	6	6	*
	20-34	37	39	*
	35-49	104	140	*
	50+	158	258	*
Total HA:		305	443	219

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	190	277	138
Female	115	166	81

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	219	51	560	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
NORTHERN Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH EAST	10 years or more	22	10
	5 years or more	14	9
	<5 years	7	5
	Total HSDA:	43	24
NORTH WEST	10 years or more	35	28
	5 years or more	19	14
	<5 years	12	11
	Total HSDA:	66	53
NORTHERN INTERIOR	10 years or more	85	63
	5 years or more	63	44
	<5 years	48	35
	Total HSDA:	196	142
Total HA:		305	219

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	142	101
	5 years or more	96	67
	<5 years	67	51
Total HA:		305	219

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries
NORTHERN Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH EAST	40	62	3	*
NORTH WEST	83	166	18	*
NORTHERN INTERIOR	118	465	21	*
Total:	241	693	42	230

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH EAST	10
NORTH WEST	18
NORTHERN INTERIOR	12
Total:	40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

HA	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
INTERIOR	EAST KOOTENAY	6	10	5
	KOOTENAY BOUNDARY	6	9	6
	OKANAGAN	26	42	17
	THOMPSON/CARIBOO/SHUSWAP	24	47	16
	Total HA:	62	108	44
FRASER	FRASER EAST	35	46	23
	FRASER NORTH	50	87	38
	FRASER SOUTH	81	114	60
	Total HA:	166	247	121
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	25	48	22
	RICHMOND	10	15	7
	VANCOUVER	484	879	381
	Total HA:	519	942	410
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	51	82	42
	NORTH VANCOUVER ISLAND	19	28	15
	SOUTH VANCOUVER ISLAND	40	84	32
	Total HA:	110	194	89
NORTHERN	NORTH EAST	12	15	8
	NORTH WEST	25	57	21
	NORTHERN INTERIOR	75	115	60
	Total HA:	112	187	89
Total:		969	1678	753

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	612	1076	475
Female	357	602	278

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total:	753	52	510	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





5.1 Drug Names and Definitions

Abacavir (Ziagen, ABC): a NUCLEOSIDE ANALOG from ViiV Healthcare.

Active: persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

Amphotericin B (Fungilin): a drug used for treatment of candidiasis and other fungal infections.

Amprenavir (Agenerase, APV): a PROTEASE INHIBITOR from ViiV Healthcare. No longer marketed in Canada.

Antiretroviral (ARV): a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

Atazanavir (Reyataz, ATV): a PROTEASE INHIBITOR from Bristol-Myers Squibb.

Atovaquone (Mepron): a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

Atripla (ATP): the Bristol-Myers Squibb and Gilead trade name for a tablet containing EFAVIRENZ, TENOFOVIR DF and EMTRICITABINE.

Azithromycin (Zithromax): an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

Bictegravir: an INTEGRASE INHIBITOR from Gilead Sciences.

Boosted PI: a PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

CD4 Cell Count: the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

Chemokine Receptor Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

Clarithromycin (Biaxin): an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

Cobicistat: a pharmacokinetic enhancer (“booster”) given with other antiretrovirals to improve drug exposure. Cobicistat has no anti-HIV activity. It is currently available as a component of STRIBILD, GENVOYA and PREZCOBIX.

Combination Therapy: initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

Combivir (CBV): the ViiV Healthcare trade name for a tablet containing both ZIDOVUDINE and LAMIVUDINE.

Complera (CPL): the Gilead trade name for a tablet containing EMTRICITABINE, RILPIVIRINE and TENOFOVIR DF.

Darunavir (Prezista, DRV): a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Deceased: persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.





Monthly Report

Descovy (DSC): the Gilead trade name for a tablet containing EMTRICITABINE and TENOFOVIR AF.

Didanosine (Videx, DDI): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Dolutegravir (Tivicay, DTG): an INTEGRASE INHIBITOR from ViiV Healthcare.

Doravirine: a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Merck.

Efavirenz (Sustiva, Auro efavirenz, EFV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

Elvitegravir (EGV): an INTEGRASE INHIBITOR from Gilead Sciences. It is currently available as a component of STRIBILD.

Emtricitabine (FTC): a NUCLEOSIDE ANALOG from Gilead Sciences. It is currently available as a component of TRUVADA and other combinations.

Enfuvirtide (Fuzeon, T20): a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

Entry Inhibitor: a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

Etravirine (Intelence, ETV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Ethambutol (Myambutol): an antibiotic used in COMBINATION THERAPY for treatment of mycobacterial infections such as tuberculosis and mycobacterium avium complex (MAC).

First started program: a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

Fosamprenavir (Telzir, fAPV): a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

Fusion Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

Genvoya (GNV): the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICSTAT, EMTRICITABINE and TENOFOVIR AF.

Granulocyte Colony Stimulating Factor (GCSF, Neupogen): a natural hormone that stimulates production of granulocytes, a type of white blood cell (leukocyte).

Health Authority: refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

Inactive: persons no longer dispensed drugs through the HIV/AIDS Drug Treatment program this current month.

Integrase Inhibitor: a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

Kivexa (KIV): the ViiV Healthcare's trade name for a tablet containing both ABACAVIR and LAMIVUDINE.

Lamivudine (3TC): a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.

Lopinavir (Kaletra, LPV/r): a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.





Maraviroc (Celsentri, MVC): a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by blocking the binding site of the CCR5 co-receptor.

Median (MED) age: median age of participants in the HIV/AIDS Drug Treatment program in that time period.

MDRT: see MULTIPLE DRUG RESCUE THERAPY

Moved out of BC: a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.

Moxifloxacin: a fluoroquinolone antibiotic that is used for treatment of mycobacterium avium complex which is resistant to clarithromycin.

Multiple Drug Rescue Therapy (MDRT or Mega-HAART): the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

Nelfinavir (Viracept, NFV): a PROTEASE INHIBITOR from ViiV Healthcare.

Net change: the net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

Nevirapine (Viramune, NVP): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

NNRTI: see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

NNRTI / no PI: a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI): a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

NRTI: see NUCLEOSIDE ANALOG.

Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI): a type of ANTIVIRAL drug whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

Nucleotide Analog: ANTIVIRAL compounds that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

Octreotide Acetate (Sandostatin): a drug used to treat chronic refractory diarrhea.

Odefsey (ODF): the Gilead trade name for a tablet containing RILPIVIRINE, EMTRICITABINE and TENOFOVIR AF.

One or more PI: a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

Other: an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).

Paromomycin (Humatin): an antibiotic used to treat infections caused by intestinal parasites, including AIDS-related cryptosporidiosis.





Monthly Report

Pentamidine: an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).

PI: see PROTEASE INHIBITOR.

Prezcobix (PZC): the Janssen trade name for a tablet containing DARUNAVIR and COBICISTAT.

Prodrug: a compound that is converted within the body into the active form that has medical effects.

Protease Inhibitor: a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.

Raltegravir (RGV, Isentress): an INTEGRASE INHIBITOR from Merck.

Restarted/ changed therapy (Tx): a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.

Rifabutin (Mycobutin): an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

Rilpivirine (Edurant, RPV): a NON-NUCELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

Ritonavir (Norvir, RTV): a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure (“booster”).

Saquinavir (Invirase, SQV): a PROTEASE INHIBITOR from Hoffman-La Roche.

Stavudine (Zerit, d4T): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Stopped all therapies (Tx): a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

Stribild (STR): the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR DF.

Tenofovir alafenamide (Tenofovir AF, TAF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV. It is currently available as a component of DESCOVY and GENVOYA.

Tenofovir disoproxil fumarate (Viread, Tenofovir DF, TDF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

Tipranavir (Aptivus, TPV): a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

Triple Therapy: the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

Triumeq (TRQ): the ViiV Healthcare’s trade name for a tablet containing DOLUTEGRAVIR, ABACAVIR and LAMIVUDINE.

Trizivir (TRZ): the ViiV Healthcare’s trade name for a tablet containing ABACAVIR, ZIDOVUDINE and LAMIVUDINE.

Truvada (TRU): the Gilead trade name for a tablet containing TENOFOVIR DF and EMTRICITABINE.





Monthly Report

Valganciclovir: an antiviral drug used to treat cytomegalovirus (CMV) retinitis.

Viral Load: the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

Zidovudine (Retrovir, AZT): a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.

